about
Feasibility of Administering High-Dose (131) I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms.High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastomaArsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomideA phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumorsA focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy.Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastomaReduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.Results of multimodal treatment for desmoplastic small round cell tumors.Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma.Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study.Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastomaStriking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.Myeloablative chemotherapy with autologous stem cell transplant for desmoplastic small round cell tumorProlonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study.Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma.Antibody-based targeted radiation to pediatric tumors.Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remissionEnrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.Salvage rates after progression of high-risk neuroblastoma with a soft tissue massLack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.Osteochondroma in long-term survivors of high-risk neuroblastoma.Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma.Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine.Biodistribution and dosimetry of (18)F-Meta Fluorobenzyl Guanidine (MFBG): A first-in-human PET-CT imaging study of patients with neuroendocrine malignancies.Desmoplastic small round cell tumor 20 years after its discovery.Management of desmoplastic small round cell tumorAcute pain relief after Mantram meditation in children with neuroblastoma undergoing anti-GD2 monoclonal antibody therapy.Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma.Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9.Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan.Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy.Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission.Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastoma.Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma.
P50
Q30730580-0C67745B-3031-4976-8ECD-731130DD6D8DQ33392673-0DBAF5CC-AF60-4DCE-920B-1F0C72E02679Q33408675-3AFBE354-222E-4990-991E-DB98CCAFCFA3Q33428982-CA2D6184-39EC-4573-8A59-17B0B9388FCFQ33438006-583CBCD2-E7F8-459E-A195-B7FFA182A319Q33438641-77757C74-3199-4FA8-BA19-B41D4460DBC9Q33441248-8D66CEA1-2B16-4836-B233-7428737546CBQ33566420-619C8652-E288-424C-8EF1-A84ED12D6E16Q33764664-400D2DE1-A96C-41F1-8A1E-36E781BFA81AQ33836071-CBF3C5EA-7AF5-4182-BB42-D4A5F8FCF87DQ33836091-97292744-ADD6-4D63-B702-216EF6400DA1Q34378537-0CD4006B-922A-44F6-B53A-10D50E308E01Q34415679-3EF486EC-63BB-42BC-A1BB-70948B29007FQ34582869-19837EF7-99B6-485B-B61E-39C0F7EDED60Q34590375-88057DD4-96F8-4FE5-BFE1-F62D17CF0AE7Q34877582-E4238CCB-165F-4499-8E05-328720842D4EQ34939364-A9569E31-B06A-41E0-9EC0-7C0525ECDBE0Q35077703-559A57F6-1DCC-4502-AD2B-83833EF39AD8Q35508728-6B5FD0F4-9AF5-4DB2-92BA-246353812575Q35798960-A8BDB796-96EB-4205-B0CF-A5791AFF4BD7Q36002340-A5C67F21-CCE1-4696-924B-5B6DF16A4A48Q36011317-4BD59392-2D97-4D9F-872A-31013858BC10Q36212437-2C5EFFFB-4A2A-444D-8170-9BDC9B4D7DA0Q36229462-CF9CB324-A5BD-473D-8985-07EF68AB4711Q36626994-9976CC52-DDEE-490A-B762-EA6119A6A960Q36782374-60AB52F5-0B2A-4593-BCD7-5F439F68774CQ37145905-9980F050-0260-4500-A2C2-088091E06714Q37155585-E746FC95-37C9-4C28-B658-AB2D7A503F25Q38474631-17B962D3-0BDB-4782-A1B6-A8C179E8DFE8Q38680116-9F8AA91A-3B4C-44AA-9F59-106F7D3F1C5BQ39025917-C808ECCF-2727-41D3-9E98-2849E1E3744CQ39036554-ED953251-A79D-4BF3-BBA1-04DCB59156E9Q39220169-5775071D-0708-4592-A067-CE74E9FC13B0Q40129277-76C6D78D-EBBD-409B-B14A-24BD3746A89BQ40358118-C2F58ED4-8C28-44A7-AAEB-8FBE3765D6BCQ40428815-EC00F5BB-9534-4A50-98E7-66D5B7C62309Q40631263-1DA34861-A92C-4744-BA46-04CA4975AE40Q41394300-F82EA92F-C338-4FA3-B62F-272946D11C07Q41634067-0C68D6C5-C9A2-4BE5-A9AC-0C1C7D47589BQ41644455-365D22D8-DE5B-40E2-B6C3-DEC0213553CD
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Shakeel Modak
@ast
Shakeel Modak
@en
Shakeel Modak
@es
Shakeel Modak
@nl
Shakeel Modak
@sl
শাকিল মোদক
@bn
type
label
Shakeel Modak
@ast
Shakeel Modak
@en
Shakeel Modak
@es
Shakeel Modak
@nl
Shakeel Modak
@sl
শাকিল মোদক
@bn
prefLabel
Shakeel Modak
@ast
Shakeel Modak
@en
Shakeel Modak
@es
Shakeel Modak
@nl
Shakeel Modak
@sl
শাকিল মোদক
@bn
P106
P31
P496
0000-0002-7280-1726